Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07335965

Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia

Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.

A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Laboratoire de Bactériologie - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Émilie TALAGRAND-REBOUL, MD

CONTACT

[email protected]

33 3 69 55 14 57

Émilie TALAGRAND-REBOUL, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Minor or adult subject
  • Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg

Exclusion criteria

  • Refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. Clinical and biological description of cases of recurrent imported borreliosis

    Time frame: Up to 12 years

    This study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Émilie TALAGRAND-REBOUL, MD

CONTACT

[email protected]

33 3 69 55 14 57

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Study of the Clinical, Microbiological, and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the Borrelia National Reference Center

Acronym: BORRECUR

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 13, 2026
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.